Chronic Kidney Disease

Trump administration officials said the new payment incentives represent the biggest change in kidney care in decades.

Kidney cancer rose at least 3% a year during the years studied among adolescents and young adults, according to data from the American Cancer Society.

Members of Congress introduce a bill to force Medicare to cover a drug they say will protect CKD patients during the COVID-19 pandemic.

A study suggests cardiac rehabilitation offers the most benefits to patients who start out with more advanced renal disease.

In the past 30 years, we've never seen a heart failure drug that has had such a beneficial effect on the kidneys, said Milton Packer, MD, a distinguished scholar in cardiovascular science at Baylor University Medical Center in Dallas, and chair of the department of clinical sciences at the University of Texas Southwestern Medical School.

Kidney failure is one of the expensive conditions in health care, but new results from the DAPA-CKD trial could change the equation in favor of prevention.

A Dutch study shows how genetic testing can help couples avoid passing devastating kidney diseases to their children, but it raises issues of disparities.

A proprietary algorithm can help payers identify patients at high risk of progressive chronic kidney disease.

German researchers find viral RNA in kidneys of patients who died from COVID-19.

An HHS report outlines efforts to reduce kidney failure and increase options such as home-based dialysis. COVID-19 has made kidney care a higher priority.

A new rule makes it impossible for patients with end-stage renal disease (ESRD) to take part in Medicare Advantage, leaving them out of coordinated care.

A Marshall University researcher received $444,000 from NIH to continue researching a new treatment target in chronic renal failure.

A rule change to let those with end-stage renal disease enroll in Medicare Advantage has a twist that could stop patients from learning if their dialysis center iis in the network.

The American College of Cardiology updates guidance on prescribing SGLT2 inhibitors and GLP-1 receptor agonists to patients with type 2 diabetes and cardiovascular disease or CV risk.